Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 04, 2021 16:05 ET | Source: Zogenix, Inc

Zogenix Provides Corporate Update and Reports Third Quarter 2021 Financial Results

FINTEPLA® net product sales of $21.4 million and total revenue of $22.6 million in the third quarter, representing quarter-over-quarter increases of 22% and 20%, respectivelySubmitted supplemental New...
November 01, 2021 08:00 ET | Source: Zogenix, Inc

Zogenix to Host Key Opinion Leader Webinar on Thymidine Kinase 2 Deficiency and MT-1621

EMERYVILLE, Calif., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Zogenix (NASDAQ: ZGNX), a global biopharmaceutical company developing rare disease therapies, today announced that it will host a key opinion...
October 21, 2021 08:00 ET | Source: Zogenix, Inc

Zogenix to Release Third Quarter 2021 Financial Results and Host Conference Call and Webcast on November 4

EMERYVILLE, Calif., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Zogenix (NASDAQ: ZGNX), a global biopharmaceutical company developing rare disease therapies, today announced data that it will report its...
October 19, 2021 08:00 ET | Source: Zogenix, Inc

Zogenix Reports Granting of Inducement Awards

EMERYVILLE, Calif., Oct. 19, 2021 (GLOBE NEWSWIRE) -- Zogenix (NASDAQ: ZGNX) today announced that the compensation committee of the company’s board of directors granted inducement awards to...
September 30, 2021 08:00 ET | Source: Zogenix, Inc

New FINTEPLA® (Fenfluramine) Data Show Long-Term Seizure Frequency Reductions in Patients with Lennox-Gastaut Syndrome (LGS)

Median reduction in drop seizure frequency was 39.4% at 3 months (n= 227; p<0.0001) and 51.8% for patients assessed over months 10 to 12 (n=170; p<0.0001).A Supplemental New Drug Application...
September 28, 2021 08:00 ET | Source: Zogenix, Inc

Zogenix Submits Supplemental New Drug Application for FINTEPLA® (Fenfluramine) for the Treatment of Seizures Associated with Lennox-Gastaut Syndrome

Supplemental New Drug Application (sNDA) submission is supported by existing clinical data, including positive data from Company’s Phase 3 trial, Study 1601, in which the primary endpoint was met with...
September 16, 2021 17:39 ET | Source: Zogenix, Inc

Zogenix Reports Granting of Inducement Awards

EMERYVILLE, Calif., Sept. 16, 2021 (GLOBE NEWSWIRE) -- Zogenix (NASDAQ: ZGNX) today announced that the compensation committee of the company’s board of directors granted inducement awards to...
August 26, 2021 08:00 ET | Source: Zogenix, Inc

Zogenix Receives Orphan Drug Designation for FINTEPLA® (Fenfluramine) in Japan

Zogenix plans to submit a new drug application (J-NDA) for FINTEPLA in Japan for the treatment of seizures associated with Dravet syndrome by year end.Dravet syndrome is a rare, life-long form of...
August 16, 2021 17:02 ET | Source: Zogenix, Inc

Zogenix Reports Granting of Inducement Awards

EMERYVILLE, Calif., Aug. 16, 2021 (GLOBE NEWSWIRE) -- Zogenix (NASDAQ: ZGNX) today announced that the compensation committee of the company’s board of directors granted inducement awards to fourteen...
August 05, 2021 16:01 ET | Source: Zogenix, Inc

Zogenix Provides Corporate Update and Reports Second Quarter 2021 Financial Results

Commercial launches of FINTEPLA® in the U.S. and Europe progressing strongly, with total net product sales of $17.5 million and total revenue of $18.8 million in the second quarter, representing...